Sonic Healthcare USA (SHUSA) has acquired the assets of Cairo Diagnostics, enhancing its haematology oncology testing capabilities in the US.
Based in White Plains, New York, Cairo Diagnostics operates accredited laboratories specialising in hematopathology and oncology diagnostics.
SHUSA, a part of Australia-based diagnostics company Sonic Healthcare, provides pathology services across the US.
With the acquisition, Cairo will integrate its services into SHUSA’s network.
It will use SHUSA’s logistics and commercial operations to enhance patient care and physician support across the US.
The acquisition is contingent on satisfying certain customary regulatory approvals.
Sonic Healthcare USA CEO Cory Roberts said: “This acquisition reflects Sonic’s commitment to medical leadership in practice, not just in words.
“By bringing Cairo’s integrated oncology platforms into Sonic’s network, we expect to access, service and support oncologists nationwide, expanding the reach of Cairo’s expertise while strengthening SHUSA’s capabilities in high-complexity oncology diagnostics.”
Sonic Healthcare USA chief medical officer Mohammed Salama said: “By combining Cairo’s comprehensive menu with SHUSA’s nationwide infrastructure, we can deliver faster, more complete answers to care teams.
“This acquisition positions us to expand into areas of innovation – including liquid biopsy and other emerging technologies, that will help anticipate the evolving needs of oncology care.”
Established in 2013, Cairo Diagnostics combines various diagnostic disciplines under one roof to reduce delays associated with multiple-lab testing.
Its integration with SHUSA supports oncologists with timely, comprehensive reports, fostering informed treatment decisions.
The acquisition is expected to streamline decision-making, minimising diagnosis delays and potentially improving patient outcomes nationwide.
Upon closing, SHUSA plans to expand Cairo’s capabilities across the US, making its advanced diagnostics more accessible.
Furthermore, the acquisition promises improved access to integrated results for patients and physicians alike, capitalising on Sonic’s established infrastructure and industry relationships.
Cairo Diagnostics founder Dr. Sherif Ibrahim said: “Becoming part of Sonic Healthcare USA will allow that same quality and speed in oncology testing to reach providers and patients nationwide, while maintaining the responsive and personal approach that has defined us from the start.
“Few national providers combine this breadth of high-complexity haematology oncology testing under one roof that offers both comprehensiveness and speed with turnaround times measured in days rather than weeks.
“With Sonic’s national infrastructure, we believe we can help address that need at scale. Behind every test result is a patient waiting for answers. By partnering with Sonic Healthcare USA, we can bring our service model to communities nationwide, supporting oncologists with the clarity they need when it matters most.”
Last year, Sonic Healthcare agreed to acquire LADR (Laboratory Group Dr. Kramer & Colleagues), a Germany-based medical laboratory group.
